Dr. Paul Ridker and Dr. C. Michael Gibson Discuss: CLEAR OUTCOMES subanalysis on predicting CV events November 13, 2023 Disclosures: TBD
Dr. Richard Wright and Dr. C. Michael Gibson Discuss: The Genetic / Mendalian randomization (natures randomized trial) data that supports the efficacy of Acoramadis in amyloidosis and the potential for amyloid regression with therapy November 13, 2023 Disclosures: TBD
Dr. Charalambos Antoniades and Dr. C. Michael Gibson Discuss: Novel AI Technology to Improve Risk Stratification of Patients Without Obstructive Coronary Artery Disease Undergoing CCTA: The Oxford Risk Factors and Non-Invasive Imaging (ORFAN) Study November 13, 2023 Disclosures: TBD
Dr. Alexander Fanaroff Presents: A Cluster Randomized Trial of Automated Referral to Centralized Pharmacy Services for Evidence-Based Statin Initiation in High-Risk Patients November 13, 2023 Disclosures: TBD
Dr. Daniel Judge and Dr. C. Michael Gibson: Acoramidis from bench to bedside November 12, 2023 Disclosures: TBD
Dr. Steven Nissen and Dr. C. Michael Gibson Discuss: Efficacy and Safety of Lepodisiran: An Extended Duration Short-Interfering RNA Targeting Lipoprotein (a) November 12, 2023 Disclosures: TBD
Dr. Andrew Bellinger, Dr. Sek Kathiresan and Dr. C. Michael Gibson Discuss: Safety and Pharmacodynamic Effects of VERVE-101, an Investigational DNA Base Editing Medicine Designed to Durably Inactivate the PCSK9 Gene and Lower LDL Cholesterol – Interim Results of the Phase 1b heart-1 Trial November 12, 2023 Disclosures: TBD
Dr. Nina Becher and Dr. C. Michael Gibson Discuss: Efficacy and Safety of Anticoagulation With Edoxaban in Patients With AHRE Durations ≥24 Hours. The NOAH-AFNET 6 Trial November 12, 2023 Disclosures: TBD
Dr. Christian T Ruff and Dr. C. Michael Gibson Discuss: Abelacimab, a Novel Factor XI/XIa Inhibitor, vs Rivaroxaban in Patients with Atrial Fibrillation: Primary Results of the AZALEA-TIMI 71 Randomized Trial November 12, 2023 Disclosures: TBD
Dr. George Bakris and Dr. C. Michael Gibson Discuss: Sustained Blood Pressure Reduction With the RNA Interference Therapeutic Zilebesiran: Primary Results From KARDIA-1, a Phase 2 Study in Patients With Hypertension November 11, 2023 Disclosures: TBD
